Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT

Gabriele Manzella1, Leonie D Schreck1, Willemijn B Breunis1,2

  • 1University Children's Hospital, Department of Oncology and Children's Research Center, Steinwiesstrasse 75, CH-8032, Zurich, Switzerland.

Nature Communications
|September 16, 2020
PubMed

Insights

This study introduces a new in vitro drug profiling platform for rhabdomyosarcoma (RMS) using patient-derived xenografts. The platform enables personalized treatment selection by identifying patient-specific drug sensitivities, particularly to AKT inhibitors.

Area of Science:

  • Oncology
  • Translational Medicine
  • Drug Discovery

Background:

  • Cancer therapy is transitioning towards personalized medicine, but identifying targeted therapies remains challenging.
  • Druggable oncogenes are found in a limited number of cancer patients.
  • Functional profiling of primary tumor cells offers an alternative but lacks suitable platforms for many cancers.

Purpose of the Study:

  • To develop and validate an in vitro drug profiling platform for rhabdomyosarcoma (RMS).
  • To enable high-throughput drug testing using a living biobank of RMS patient-derived xenografts (PDX).
  • To facilitate patient-specific treatment selection in a co-clinical setting.

Main Methods:

  • Established a living biobank of twenty RMS patient-derived xenografts (PDX).
  • Optimized in vitro conditions to maintain phenotypic and molecular characteristics of PDX cells.
  • Performed high-throughput drug screening using a large drug library on primary RMS cells.

Main Results:

  • The developed platform successfully preserved key characteristics of primary RMS cells.
  • Drug profiling revealed heterogeneous, patient-specific drug responses.
  • A significant subgroup of RMS demonstrated strong sensitivity to AKT inhibitors.

Conclusions:

  • The study demonstrates the feasibility of an in vitro drug profiling platform for RMS.
  • This platform supports patient-specific treatment selection by identifying individual drug vulnerabilities.
  • The findings highlight the potential of AKT inhibitors for a subset of RMS patients.

Related Concept Videos